- Home
- CRGX vs MBI Comparison
CRGX vs MBI Comparison
Compare CRGX & MBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- MBI
- Stock Information
- Founded
- CRGX 2021
- MBI 1973
- Country
- CRGX United States
- MBI United States
- Employees
- CRGX N/A
- MBI N/A
- Industry
- CRGX
- MBI Property-Casualty Insurers
- Sector
- CRGX
- MBI Finance
- Exchange
- CRGX Nasdaq
- MBI Nasdaq
- Market Cap
- CRGX 213.5M
- MBI 222.1M
- IPO Year
- CRGX 2023
- MBI 1987
- Fundamental
- Price
- CRGX $4.52
- MBI $4.95
- Analyst Decision
- CRGX Hold
- MBI Buy
- Analyst Count
- CRGX 7
- MBI 2
- Target Price
- CRGX $5.33
- MBI $6.25
- AVG Volume (30 Days)
- CRGX 3.0M
- MBI 201.7K
- Earning Date
- CRGX 08-11-2025
- MBI 08-05-2025
- Dividend Yield
- CRGX N/A
- MBI N/A
- EPS Growth
- CRGX N/A
- MBI N/A
- EPS
- CRGX N/A
- MBI N/A
- Revenue
- CRGX N/A
- MBI $37,000,000.00
- Revenue This Year
- CRGX $57.81
- MBI N/A
- Revenue Next Year
- CRGX N/A
- MBI N/A
- P/E Ratio
- CRGX N/A
- MBI N/A
- Revenue Growth
- CRGX N/A
- MBI 285.71
- 52 Week Low
- CRGX $3.00
- MBI $3.22
- 52 Week High
- CRGX $25.45
- MBI $7.46
- Technical
- Relative Strength Index (RSI)
- CRGX 54.72
- MBI 64.85
- Support Level
- CRGX $4.40
- MBI $4.87
- Resistance Level
- CRGX $4.63
- MBI $5.15
- Average True Range (ATR)
- CRGX 0.07
- MBI 0.17
- MACD
- CRGX -0.01
- MBI 0.05
- Stochastic Oscillator
- CRGX 34.29
- MBI 75.66
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About MBI MBIA Inc.
MBIA Inc provides financial guaranty insurance for municipal bonds and asset-backed securities in the United States and internationally. It offers an unconditional guarantee to repay the principal and interest on these securities if the issuer defaults. MBIA insures bonds sold in the primary and secondary markets, as well as those held in unit investment trusts and mutual funds. It operates in three segments: the United States Public Finance Insurance, which derives maximum revenue, Corporate, and International & Structured Finance Insurance. U.S. public finance insurance portfolio is managed through the National Public Finance Guarantee Corporation. International & structured finance insurance business is managed through MBIA Insurance Corporation and its subsidiary.